24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling ; volume:15 ; number:1 ; day:30 ; month:3 ; year:2017 ; pages:1-13 ; date:12.2017
Journal of translational medicine ; 15, Heft 1 (30.3.2017), 1-13, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Baty, Florent
- Contributor
-
Joerger, Markus
Früh, Martin
Klingbiel, Dirk
Zappa, Francesco
Brutsche, Martin
SpringerLink (Online service)
- DOI
-
10.1186/s12967-017-1174-z
- URN
-
urn:nbn:de:1111-201704174291
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Baty, Florent
- Joerger, Markus
- Früh, Martin
- Klingbiel, Dirk
- Zappa, Francesco
- Brutsche, Martin
- SpringerLink (Online service)
Other Objects (12)
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
24H Schwimmen ´12
24hBerlin, [Textbd.]
24H Schwimmen ´11
24H Schwimmen ´13
24H Schwimmen ´14
24H Schwimmen ´10
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
Diagramm Weizenmühle 300t/24h
Tillmannsweg 24h (Zehlendorf/Wannsee)
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
24H Schwimmen ´12
24hBerlin, [Textbd.]
24H Schwimmen ´11
24H Schwimmen ´13
24H Schwimmen ´14
24H Schwimmen ´10
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
Diagramm Weizenmühle 300t/24h
Tillmannsweg 24h (Zehlendorf/Wannsee)
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results
24H Schwimmen ´12
24hBerlin, [Textbd.]
24H Schwimmen ´11
24H Schwimmen ´13
24H Schwimmen ´14
24H Schwimmen ´10
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
Diagramm Weizenmühle 300t/24h